Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie for å lære om studiemedisinen Aztreonam-Avibactam (ATM-AVI) hos spedbarn og nyfødte innlagt på sykehus med bakteriell infeksjon (CHERISH) (CHERISH)

14. oktober 2026 oppdatert av: Pfizer

En fase 2a, 2-delt, åpen etikett, ikke-randomisert, multisenter, enkelt- og flerdoseforsøk for å evaluere farmakokinetikk, sikkerhet og tolerabilitet av Aztreonam og Avibactam ± Metronidazol hos nyfødte og spedbarn fra fødsel til under 9 måneders alder med Mistenkte eller bekreftede infeksjoner på grunn av gramnegative patogener som krever intravenøs antibiotikabehandling

The purpose of this study is to learn about the safety and effects of ATM-AVI for the possible treatment of infections caused by a type of bacteria called gram-negative bacteria.

The study medicine is a combination of an antibiotic, aztreonam (ATM), and another medicine, avibactam (AVI), which is used to help stop bacteria from being resistant to antibiotics. Antibiotics are medicines that fights bacteria and infections.

The study will include newborns and infants up to 9 months of age who are admitted in the hospital.

The study is conducted in 2 parts: Part A and Part B.

In Part A, all participants will receive a single intravenous (injected directly into a vein) infusion of ATM-AVI. This is to study the safety and effects of a single amount.

In Part B, all participants will receive multiple intravenous infusions of ATM-AVI as treatment for a possible or confirmed infection with gram-negative bacteria.

Studieoversikt

Detaljert beskrivelse

This is a 2-part Phase 2a, non-randomized, multicenter, open-label, single and multi-dose study to assess pharmacokinetics (PK), safety, and tolerability of ATM-AVI in hospitalized neonates and infants aged birth, including preterm birth, to <9 months. A total of 48 participants will be enrolled in 4 age cohorts of 12 each, 6 Part A and 6 Part B. Part A will begin enrolling before Part B and no infant may participate in both parts. Cohort 1 will include full term infants age ≥13 weeks to <39 weeks and preterm infants postmenstrual age ≥50 weeks to <75 weeks. Cohort 2 will include full term infants age ≥28 weeks to <13 weeks and preterm infants postmenstrual age ≥40 weeks to <50 weeks and ≥28 days of age. Cohort 3 will include full term infants age birth to <28 days. Cohort 4 will include preterm infants age birth to <28 days or postmenstrual age <40 weeks.

Participants in Part A must be hospitalized and receiving intravenous antibiotic treatment for a suspected or confirmed bacterial infection. Participants will receive a single 3 hour intravenous infusion of ATM-AVI and have 3 ATM-AVI blood level assessments during and up to 5 hour after the infusion. Participants will be observed for 48 hours following the infusion to assess safety and toleration and will have a final follow-up safety assessment which may be conducted by telephone 4-5 weeks following the infusion. The single infusion of ATM-AVI is administered to assess the safety, tolerability, and pharmacokinetics of a single dose of ATM-AVI and is not intended as treatment for the bacterial infection. The total duration of study participation in Part A is expected to be 5 weeks through the end of the final safety follow-up.

Participants in Part B must be hospitalized with suspected or confirmed aerobic gram-negative bacterial infection requiring intravenous antibacterial therapy. Part B participants will receive multiple 3 hour intravenous infusions of ATM-AVI every 6 hour (8 hours for preterm infants) for 3-14 days as treatment for their bacterial infection and to assess ATM-AVI pharmacokinetics, safety, tolerability, and efficacy. Participants with complicated intra-abdominal infection (cIAI) will also receive intravenous metronidazole and all participants will have the option to receive other intravenous antibiotic treatment for gram-positive bacteria, as appropriate. Participants who have a good clinical response after 72 hours of intravenous ATM-AVI treatment may be switched to a different orally administered antibiotic, if clinically appropriate. Part B participants will have a total of 5 ATM-AVI blood level assessments over the first 2 or more days following the start of ATM-AVI infusions and will have their clinical response assessed at the End of Treatment (intravenous and oral, if applicable), and at a Test-of-Cure (TOC) evaluation 7 to 14 days after the last antibiotic treatment (intravenous or oral). A final safety assessment which may be conducted by telephone will occur 4-5 weeks after the last dose of ATM-AVI. The total duration of study participation in Part B is expected to be up to 7 weeks through the end of the final safety follow-up.

Additional safety monitoring will be provided by an independent external Data Monitoring Committee (DMC). Enrollment for the study will begin with Part A, single dose, cohorts 1-3. Part A Cohort 4 (preterm neonates) will commence enrollment after sponsor and DMC review of plasma drug levels and safety for a least 2 participants in Part A Cohort 3 and review of ATM-AVI safety and tolerability for all participants enrolled at that time. Enrollment in the multidose Part B cohorts will be delayed until preliminary information is obtained regarding ATM-AVI multidose safety, tolerability, and drug levels for the participants 9 months to 2 years of age in the separate ongoing ATM-AVI pediatric study C3601008 [NCT05639647].

Studietype

Intervensjonell

Registrering (Antatt)

48

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Buenos Aires
      • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 1039
        • Rekruttering
        • Sanatorio Sagrado Corazón
      • Mar del Plata, Buenos Aires, Argentina, 7600
        • Rekruttering
        • Clinica Del Niño Y La Madre
    • Córdoba Province
      • Córdoba, Córdoba Province, Argentina, X5000IIH
        • Rekruttering
        • Clinica Privada del Sol S.A
    • Tucumán Province
      • San Miguel de Tucumán, Tucumán Province, Argentina, 4000
        • Rekruttering
        • Hospital del Niño Jesús
      • Burgas, Bulgaria, 8000
        • Rekruttering
        • UMHAT Deva Maria
      • Rousse, Bulgaria, 7002
        • Rekruttering
        • Umhat Kanev
    • California
      • Orange, California, Forente stater, 92868
        • Rekruttering
        • Children's Hospital of Orange County
      • Orange, California, Forente stater, 92868
        • Rekruttering
        • Children's Hospital of Orange County Southwest Tower
    • Colorado
      • Aurora, Colorado, Forente stater, 80045
        • Rekruttering
        • Children's Hospital Colorado
    • Indiana
      • Indianapolis, Indiana, Forente stater, 46202
        • Rekruttering
        • Riley Hospital for Children at Indiana University Health
    • Kentucky
      • Louisville, Kentucky, Forente stater, 40202
        • Rekruttering
        • Norton Children's Hospital
      • Louisville, Kentucky, Forente stater, 40202
        • Rekruttering
        • Novak Center for Children's Health
      • Louisville, Kentucky, Forente stater, 40202
        • Rekruttering
        • University of Louisville, Norton Children's Research Institute
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02111
        • Rekruttering
        • Tufts Medical Center
    • North Carolina
      • Durham, North Carolina, Forente stater, 27710
        • Rekruttering
        • Duke University - Main Hospital and Clinics
    • Texas
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • The University of Texas Health Science Center at Houston
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • Memorial Hermann Hospital - Texas Medical Center
    • Kentrikí Makedonía
      • Thessaloniki, Kentrikí Makedonía, Hellas, 546 42
        • Har ikke rekruttert ennå
        • Ippokrateio General Hospital of Thessaloniki
    • Gujarat
      • Surat, Gujarat, India, 395002
        • Rekruttering
        • Nirmal Hospital Pvt Ltd.
    • Karnataka
      • Bengaluru, Karnataka, India, 560074
        • Rekruttering
        • RajaRajeswari Medical College and Hospital
    • Maharashtra
      • Pune, Maharashtra, India, 411006
        • Rekruttering
        • Sahyadri Super Speciality Hospital
    • Uttar Pradesh
      • Lucknow, Uttar Pradesh, India, 226030
        • Rekruttering
        • Medanta Hospital Lucknow
    • West Bengal
      • Kolkata, West Bengal, India, 700017
        • Rekruttering
        • Institute of Child Health
    • Central District
      • Petah Tikva, Central District, Israel, 49202
        • Rekruttering
        • Schneider Children's Medical Center
    • Northern District
      • Haifa, Northern District, Israel, 3109601
        • Rekruttering
        • Rambam Health Care Campus
    • Florence
      • Florence, Florence, Italia, 50139
        • Rekruttering
        • Azienda Ospedaliera Universitaria Meyer IRCCS
      • Madrid, Spania, 28041
        • Har ikke rekruttert ennå
        • Hospital Universitario 12 de Octubre
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Spania, 28046
        • Rekruttering
        • Hospital Universitario La Paz
      • Taichung, Taiwan, 407
        • Rekruttering
        • Taichung Veterans General Hospital
      • Taoyuan, Taiwan, 33305
        • Rekruttering
        • Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital
    • Hsinchu
      • Hsinchu, Hsinchu, Taiwan, 300046
        • Rekruttering
        • Hsinchu Municipal Mackay Children's Hospital
    • Hualien
      • Hualien City, Hualien, Taiwan, 970
        • Rekruttering
        • Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

Ikke eldre enn 9 måneder (Barn)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria

Participants must meet the following key inclusion criteria to be eligible for enrollment into the study:

  1. Hospitalized with age from birth <9 months, including preterm birth
  2. Part A: Receiving IV antibiotics for treatment of suspected or confirmed bacterial infection, including but not limited to cIAI, cUTI, HAP/VAP, BSI, or sepsis.
  3. Part B: Suspected or confirmed gram-negative bacterial infection requiring IV antibiotics, including but not limited to cIAI, cUTI, HAP/VAP, BSI, or sepsis.

Participants with any of the following characteristics/conditions will be excluded:

  1. Received any other investigational medicinal product within the longer of 30 days or 5 half-lives before enrollment.
  2. Any medical or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  3. Severe renal impairment or known significant renal disease, as evidenced by elevated serum creatinine at screening, or urinary output <0.5 mL/kg/h for 6 consecutive hours or requirement for dialysis.
  4. Part B Only: Received >24 hours of systemic antibiotic treatment for gram-negative organisms at time of enrollment, unless documented treatment failure or lack of improvement in at least one objective sign or symptom of infection after ≥48 hours of antibiotics.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Part A, Cohorts 1-4

Single dose pharmacokinetics.

Single intravenous infusion of aztreonam-avibactam over 3 hours to assess pharmacokinetics, safety, and toleration.

Eksperimentell: Part B, Cohorts 1-4

Multi-dose pharmacokinetics and treatment

Multiple intravenous infusions of aztreonam-avibactam over 3 hours, repeated every 6-8 hours up to 14 days to assess pharmacokinetics, safety, toleration, and efficacy.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Maximum Predicted Plasma Concentration (Cmax) of ATM and AVI
Tidsramme: Up to Day 15

Cmax is the maximum plasma concentration of ATM and AVI as population pharmacokinetic (popPK) analysis predicts.

Up to Day 15
Area under the Concentration-Time Curve (AUC) of ATM-AVI
Tidsramme: Up to Day 15

AUC is a measure of the plasma concentration of ATM and AVI overtime as popPK analysis predicts.

Up to Day 15
Plasma Elimination Half-Life (t1/2)
Tidsramme: Up to Day 15

Half-life is the time measured for the plasma concentration of ATM and AVI to decrease by one half as popPK analysis predicts.

Up to Day 15
Apparent Clearance (CL)
Tidsramme: Up to Day 15

ATM and AVI clearance is a quantitative measure of the rate at which ATM and AVI are removed from the blood (rate at which ATM and AVI are metabolized or eliminated by normal biological processes). Clearance obtained after intravenous infusion dose (apparent clearance) is influenced by the fraction of the dose absorbed.

Up to Day 15
Plasma concentrations of ATM and AVI by nominal sampling time
Tidsramme: Up to Day 15

Plasma concentrations of ATM and AVI on Day 1 and at steady state (Day 2 or later) will be summarized by the nominal sampling time using descriptive statistics (eg number, mean, standard deviation).

Up to Day 15
Proportion of Participants reporting Adverse Events (AE)
Tidsramme: Baseline up to Day 50

Proportion of participant AE reports of vital signs, physical examinations, and clinical laboratory tests overall and by age cohort. For each AE the last assessment made prior to the first dose of study drug will be defined as the baseline.

Baseline up to Day 50
Proportion of Participants reporting Serious Adverse Events (SAE)
Tidsramme: Baseline up to Day 50

Proportion of participant SAE reports of vital signs, physical examinations, and clinical laboratory tests overall and by age cohort. For each SAE the last assessment made prior to the first dose of study drug will be defined as the baseline.

Baseline up to Day 50
Proportion of Participants reporting AEs leading to discontinuation of study drug
Tidsramme: Baseline up to Day 50

Proportion of Participants reporting AEs leading to discontinuation of study drug from baseline. For each discontinuation the last assessment made prior to the first dose of study drug will be defined as the baseline.

Baseline up to Day 50
Proportion of Participants reporting AEs resulting in death
Tidsramme: Baseline up to Day 50

Proportion of Participants reporting AE resulting in death from baseline. For each death the last assessment made prior to the first dose of study drug will be defined as the baseline.

Baseline up to Day 50
Proportion of Participants reporting liver injury and acute kidney injury
Tidsramme: Baseline up to Day 50

Proportion of Participants reporting liver injury and acute kidney injury from baseline. For each report of liver and acute kidney injury the last assessment made prior to the first dose of study drug will be defined as the baseline.

Baseline up to Day 50

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Part B: Proportion of participants with each clinical outcome and with a favorable clinical outcome at end of IV study treatment (EOIV)
Tidsramme: Up to 15 days after start of IV study treatment

Clinical Cure is defined baseline signs and symptoms improved such that no further antimicrobial treatment is required for an aerobic gram-negative baseline infection. Participants who receive treatment for gram-positive organisms or adjunctive therapy for Pseudomonas aeruginosa, as allowed per protocol, can still have a response of cure. Clinical improvement is defined as baseline signs and symptoms sufficiently improved to allow switching to an oral antibiotic treatment. A favorable outcome is clinical cure or clinical improvement. Failure is defined as a requirement for further antibiotic treatment, including following premature discontinuation due to an adverse event, or death after receiving at least 48 hours of treatment. Indeterminant is defined as data not available for evaluation of efficacy for any reason.

Up to 15 days after start of IV study treatment
Part B: Proportion of participants with each clinical outcome and with a favorable clinical outcome at end of treatment (EOT)
Tidsramme: Within 48 hours after last dose of oral switch treatment

EOT is only applicable for participants switched to an oral antibiotic treatment. Possible outcomes are cure, failure, or indeterminant.

Within 48 hours after last dose of oral switch treatment
Part B: Proportion of participants with each clinical outcome and with a favorable clinical outcome at test of cure (TOC)
Tidsramme: 7-14 days after the last study treatment

Possible outcomes are cure, failure, or indeterminant.

7-14 days after the last study treatment
Part B: Proportion of participants with a favorable microbiological response at TOC
Tidsramme: 7-14 days after the last study treatment

A favorable response is eradication or presumed eradication. Eradication is absence of the causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication is when a repeat culture was not performed and the clinical response is cure.

7-14 days after the last study treatment
Part B: Counts and proportions of pathogens with each per-pathogen microbiological response at EOIV/EOT
Tidsramme: Up to 15 days after start of IV study treatment

Possible outcomes are eradication, presumed eradication, persistence, presumed persistence or indeterminate. Presumed eradication/persistence based on repeat culture not performed and clinical outcome of cure/failure. Persistence is the causative pathogen is still present from an appropriately obtained specimen at the site of the infection. Indeterminant includes participant lost to follow-up or death after receiving less than 48 hours of study treatment.

Up to 15 days after start of IV study treatment
Part B: Counts and proportions of pathogens with each per-pathogen microbiological response at TOC
Tidsramme: 7-14 days after the last study treatment

Possible outcomes are eradication, presumed eradication, persistence, presumed persistence or indeterminate.

7-14 days after the last study treatment
Part B: Counts and proportions of participants with emergent infections (new infections or superinfections) during the study
Tidsramme: Through study completion, up to Day 50

Superinfection is defined as emergence of a new pathogen associated with worsening signs and symptoms of infection and a requirement for additional antibiotics during the period up to and including EOIV/EOT. New infection is defined as emergence of a new pathogen associated with worsening signs and symptoms of infection and a requirement for additional antibiotics during the period after EOIV/EOT.

Through study completion, up to Day 50

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Etterforskere

  • Studieleder: Pfizer CT.gov Call Center, Pfizer

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

25. september 2024

Primær fullføring (Antatt)

25. april 2027

Studiet fullført (Antatt)

25. april 2027

Datoer for studieregistrering

Først innsendt

28. mai 2024

Først innsendt som oppfylte QC-kriteriene

14. juni 2024

Først lagt ut (Faktiske)

17. juni 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

15. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

14. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • C3601010
  • 2023-507757-15-01 (Registeridentifikator: CTIS (EU))
  • 2023 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere